Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has appointed Troy Ignelzi as an independent member of its Board of Directors.
Ignelzi joins the board with more than 25 years of experience supporting life science companies in finance, business development and operations: overseeing the evolutions of privately held clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches.
Ignelzi has played a key role in seven IPOs, and currently serves as CFO of Karuna Therapeutics. He joined Karuna in March 2019, coming from scPharmaceuticals, where he was also in the role of chief financial officer overseeing its transformation to a company preparing for commercial launch.
Ignelzi’s past roles include senior positions with Juventas Therapeutics, Esperion Therapeutics and Insys Therapeutics, helping raise public and private capital and expand pipelines through licensing and acquisitions. Ignelzi holds a B.A. in accounting from Ferris State University.
Vedanta Biosciences is a founded entity of PureTech Health plc.